Amneal Adds Xolair Rival To Biosimilars Pipeline

Kashiv Biosciences-Developed Omalizumab Becomes Eighth Product In Amneal’s Roster

 
• By Dave Wallace

Amneal has revealed the latest addition to its biosimilars pipeline, in the form of an omalizumab rival to Xolair developed by Kashiv Biosciences.

Red pipes on white background
Amneal is adding to its biosimilars pipeline • Source: Shutterstock

More from Biosimilars

More from Products